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Initiating Mutation and 
Additional Mutation(s)
Genetic 
Alterations
Features of the GEMM Histology Relevant to Specific Model
Relevance to Human Lung Cancer and/or 
Technology Development
K-ras activation K-rasLSL-G12D or 
K-rasLSL-G12V
Cre-dependent expression of oncogenic 
K-rasG12D or K-rasG12V from endogenous 
locus. Viral cre delivery via adenoviral 
or lentiviral inoculation (intranasal or 
intratracheal).
Adenocarcinoma spectrum histology (i.e., in situ and 
invasive neoplasia) in lung; metastasis not reported.
K-ras somatic mutations identified in ~20%-
30% of lung adenocarcinomas. Mouse models 
of the oncogenic K-ras allele have been used 
in preclinical studies of cisplatin resistance and 
combination targeted therapies.
K-rasLSL-G12D; 
p53Fl/Fl or 
p53LSL-R270H/Fl or 
p53LSL-R172H/Fl
Viral cre-dependent expression of 
K-rasG12D and p53 mutant variants: both 
p53 alleles deleted vs. one deleted and 
one with R270H mutation or one with 
R172H mutation.
Adenocarcinoma spectrum with accelerated tumor 
progression; tumors of higher grades and more 
invasive compared to K-rasG12D alone tumors; 
metastasis to thoracic LNs and kidney; dominant 
negative effect conferred by p53 R270H allele.
p53 somatic mutations identified in ~10%-35% 
of human lung adenocarcinoma. GEMM used to 
study tumor progression and therapeutics; for 
example, NFKB inhibition or combined CDK1 and 
PARP inhibition.
K-rasLSL-G12D; 
Lkb1Fl/Fl or 
Lkb1Fl/-
Viral cre-dependent expression of 
K-rasG12D and inactivation of Lkb1.
Adenocarcinoma spectrum with accelerated tumor 
progression compared to K-rasG12D alone tumors; 
more than half of adeno-cre-treated K-ras;Lkb1Fl/
or K-ras;Lkb1Fl/- mice harbored squamous cell 
carcinomas (SCC) or adenosquamous carcinomas, 
and 2 of 27 lungs showed large cell carcinomas; 
metastasis to regional LNs and axial skeleton.
Lkb1 somatic mutations identified in 8%-
26% of human lung carcinoma and occur in 
adenocarcinoma and SCC. Integrative genomic 
and proteomic profiles of this GEMM revealed 
SRC activation and synergistic tumor regression 
by combined SRC, PI3K, and MEK1/2 inhibition.
K-rasLSL-G12D; 
p16Ink4a-/- or 
Ink4a/Arf-/-
Viral cre-dependent expression of 
K-rasG12D and p16Ink4a or Ink4a/Arf 
inactivation. 
Adenocarcinoma spectrum with higher tumor 
multiplicity seen in Ink4a/Arf-/- than in p16Ink4a-/-; few 
metastases seen in p16Ink4a-/-.
p16 (CDKN2A) somatic mutations identified in 
5%-14% of lung adenocarcinoma.
K-rasLSL-G12D; 
RbFl/Fl or 
p130Fl/Fl
Viral cre-dependent expression of 
K-rasG12D and inactivation of Rb or p130. 
Adenocarcinoma spectrum; decreased survival 
(with either Rb or p130 deletion) and higher grade 
tumors (with Rb deletion) in the setting of K-rasG12D 
expression; metastasis not reported.
Rb somatic mutations identified in 3% of human 
lung adenocarcinomas.
K-rasLSL-G12D; 
PTENFl/Fl; 
CCSP-Cre
Cre-dependent expression of K-rasG12D 
and PTEN inactivation. CCSP-Cre 
knockin.
Adenocarcinoma spectrum; increased 
tumorigenesis with more inflammation and 
vascularity compared to K-rasG12D alone.
PTEN somatic mutations identified in 3% of 
human lung carcinoma.
K-rasLA2 Latent nonfunctional allele undergoes 
spontaneous recombination to activated 
K-rasG12D.
Adenocarcinoma spectrum; at advanced stages, 
rare metastases to LNs, kidney; thymic lymphomas, 
skin papillomas also seen. 
K-ras somatic mutations identified in ~20%-30% 
of human lung adenocarcinomas.
K-rasFSF-G12D Flp-dependent activation of K-rasG12D. Same histology as K-rasLSL-G12D. Can be combined 
with FRT-flanked p53 alleles.
Enables sequential mutation in combination with 
cre-lox system.
Activated K-ras 
transgenic lines
Transgenes expressing oncogenic K-ras 
in a cre- or dox-dependent manner. 
Adenocarcinoma spectrum. Transgenic alleles may model K-ras amplification, 
which can occur in human disease.
EGFR activation TetO-EGFRL858R 
or TetO-
EGFRDel19; 
CCSP-rtTA
Transgene expressing dox-inducible 
human EGFR carrying L858R mutation or 
exon 19 in-frame deletion. CCSP drives 
rtTA expression in distal lung epithelium.
Adenocarcinoma spectrum progressing to multifocal 
invasive adenocarcinoma; L858R tumors have 
shorter latency and are more diffuse than exon 
19 deletion or inducible K-rasG12D; metastasis not 
reported.
EGFR somatic mutations identified in 23% of 
lung adenocarcinoma. L858R mutations account 
for 35%-45% of all EGFR mutations, and exon 
19 deletions account for 45%-50% of all EGFR 
mutations in adenocarcinoma. 
TetO-
EGFRL858R;T790M; 
CCSP-rtTA
Transgene expressing dox-inducible 
human EGFR carrying L858R and 
T790M mutations.
Peripheral tumors similar to L858R; unlike L858R, 
bronchial papillary neoplasias progressing to 
papillary adenocarcinomas; lymph node metastases.
T790M is a secondary EGFR mutation acquired in 
~50% of erlotinib-resistant tumors. GEMM used 
to test therapeutic strategies.
BRaf activation BRafLSL-V600E 
(BRafCA) or 
TetO-BRafV600E; 
CCSP-rtTA
Viral cre-dependent expression of 
oncogenic BRafV600E at endogenous 
locus or transgene expressing dox-
inducible BRafV600E.
Adenocarcinoma spectrum; enhanced 
adenocarcinoma formation in the setting of p53 of 
Ink4a/ARF loss.
BRAF somatic mutations identified in 2%-3% of 
human lung adenocarcinoma. MAPK pathway 
inhibition in these GEMMs caused tumor 
regression.
HER2 (Erbb2/Neu) 
activation
TetO-
hHER2YVMA; 
CCSP-rtTA
Transgene expressing dox-inducible 
human HER2 with an in-frame AYVM 
insertion at residue M774.
Variable latency depending on founder line; 
adenosquamous tumors (combination of squamous 
and glandular differentiation). 
HER2 somatic mutations identified in 1% of 
human lung carcinoma. 
EML4-ALK chimeric 
oncogene
TetO-EML4-
ALK; CCSP-
rtTA
Transgene expressing dox-inducible 
human EML4-ALK chimeric oncogene. 
Adenocarcinoma spectrum with occasional pleural 
and airspace invasion; no signet ring cells observed; 
metastasis not reported.
ALK somatic rearrangements identified in 6% of 
human lung adenocarcinoma. GEMM used to test 
therapeutic strategies.
PIK3CA (PI3K p110-α 
subunit) activation
TetO-
PIK3CAH1047R; 
CCSP-rtTA
Transgene expressing dox-inducible 
activated human PIK3CA mutant.
Adenocarcinoma spectrum; variable latency 
depending on founder line; metastasis not reported.
PIK3CA somatic mutations identified in 2% of 
human lung carcinoma. In GEMM, dual pan-PI3K 
and mTOR inhibition causes tumor regression.
Her2V659E or Her2WT or 
EgfrL858R or EgfrWT  or 
KrasG12V or PIK3CAmyr 
with Ink4a/Arf –/– 
TetO-oncogene; 
TetO-luciferase; 
CCSP-rtTA
ES cells and chimera formation are used 
to make mice that are mosaic for dox-
inducible human oncogenes in the lung 
epithelium.
Hyperplasia: PIK3CAMyr and EGFRWT; invasive 
adenocarcinoma: Her2V659E, EgfrL858R, and KrasG12V
This system enables rapid modeling of multiple 
clinically relevant oncogenic mutations on 
identical genetic backgrounds.
p53 and Rb inactivation p53Fl/Fl; RbFl/Fl Viral cre-dependent deletion of p53 
(floxed exons 2-10) and Rb (floxed 
exon 19).
Dysplastic foci with NE features progressing 
to aggressive tumors with SCLC histology; 
metastasis to bone, brain, adrenal, ovary, liver; 
rare adenocarcinomas, adenocarcinomas with NE 
features, large cell NE tumors, and carcinomas.
p53 and Rb mutations are estimated to occur 
in >90% of human SCLC. Cross-species 
comparison led to discovery of conserved 
genomic amplifications of L-MYC and NFIB in 
human and mouse SCLC.
p53Fl/Fl; RbFl/Fl; 
p130Fl/Fl
Viral cre-dependent deletion of p53 
(floxed exons 2-10), Rb (floxed exon 3), 
and p130 (floxed exon 2).
p130 loss accelerates tumor development; 
macroscopic tumors appreciated with shorter 
latency (6 months, compared to 9 months in p53Fl/Fl; 
RbFl/Fl); histology unchanged; metastasis to liver with 
shorter latency in tumors with p130 inactivation.
There are cases of p130 loss in human SCLC, 
and lower p130 protein levels are associated with 
higher histological grade, increased proliferation, 
and a trend toward decreased patient survival.
p53Fl/Fl; RbFl/Fl 
with cell type 
specific Ad-Cre
Ad5-CC10-Cre – mostly Clara cells; 
Ad5-SPC-Cre – mostly alveolar type 2 
cells; Ad5-CGRP-Cre – mostly NE cells.
Loss of p53 and Rb in CGRP- and SPC-expressing 
cells leads to SCLC, though at lower efficiency 
in SPC-expressing cells. Clara cells were largely 
resistant to transformation.
This system highlights the NE cells as the likely 
cell type of origin in most SCLC tumors and also 
provides tools to virally target cre expression to 
specific cell types in the lung.
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p53 inactivation
Lkb1 (Stk11) 
inactivation
p16Ink4a or 
Ink4a/Arf 
inactivation
Rb (Rb1) 
or p130 
inactivation
PTEN 
inactivation
p130 
inactivation
Adenovirus cell 
type specific 
promoters 
driving cre
Fl
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Over the past decade, significant progress has been made in developing mouse models of lung cancer that faithfully mimic the human disease. Lung cancer can be induced in 
mice by a variety of carcinogenesis protocols and constitutive germline mutations. We focus here on genetically engineered mouse models of lung cancer, rather than sponta-
neous mutant models or carcinogen-induced models. In particular, we highlight recent efforts to induce, in the pulmonary epithelium of adult mice, neoplastic mutations found 
in human cancer. These modeling efforts have relied predominantly on either transgene-mediated overexpression of an oncogene or recombinase-mediated manipulation of 
conditional alleles of oncogenes and tumor suppressors. These models have been used for basic studies of tumor progression and gene function in vivo, as well as for transla-
tional studies of targeted therapies and drug resistance mechanisms. The three most common types of human lung cancer and a summary of mouse modeling efforts are listed 
below.
Adenocarcinoma
More genetically engineered models have been developed of adenocarcinoma than of any other lung cancer subtype. These models use several driver oncogenes that have 
been identified in human genomic studies. The earliest known precursor of human lung adenocarcinoma is atypical adenomatous hyperplasia (AAH), and many mouse mod-
els recapitulate the entire adenocarcinoma spectrum from AAH to invasive disease. Distant metastasis has been observed in several models, although this often requires the 
manipulation of more than one gene at the time of initiation.
Squamous Cell Carcinoma
Many human squamous cell carcinomas, particularly those that arise centrally, are thought to evolve from preinvasive lesions termed bronchial dysplasia, which then progress 
to in situ and invasive carcinoma. Some mouse adenocarcinoma models develop squamous histology. However, to date, there have been no reports of a genetically engineered 
mouse model of pure squamous cell carcinoma that recapitulates the natural progression of the human disease. Future modeling efforts will likely be aided by identifying can-
didate driver oncogenes and by elucidating the correct cells of origin for this disease.
Small Cell Lung Carcinoma
In humans, small cell lung carcinoma (SCLC) is an aggressive neuroendocrine neoplasm that has usually metastasized by the time of diagnosis. In the mouse, SCLC is initiated 
by deletion of two tumor suppressors (Rb and p53) that are usually downregulated, mutated or deleted in human SCLC. Deletion of these two genes produces a model that reca-
pitulates the spectrum of human SCLC. The long latency of this model (macroscopic tumors are typically found 6–9 months after initiation) suggests that additional mutations 
are likely required for invasion and metastasis.
Abbreviations
Dox, doxycycline; FSF, FRT-Stop-FRT; GEMM, genetically engineered mouse model; LNs, lymph nodes; LSL, Lox-Stop-Lox; NE, neuroendocrine; SCC, squamous cell carci-
noma.
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